Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
Campi I, Vannucchi G, Muller I, Lazzaroni E, Currò N, Dainese M, Montacchini B, Covelli D, Guastella C, Pignataro L, Fugazzola L, Arosio M, Salvi M.
Campi I, et al. Among authors: vannucchi g.
Front Endocrinol (Lausanne). 2022 Jan 25;12:790246. doi: 10.3389/fendo.2021.790246. eCollection 2021.
Front Endocrinol (Lausanne). 2022.
PMID: 35145479
Free PMC article.